Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of sodium foscarnet injection, expanding the company's product line [1] Group 1: Product Approval - The approved indications for the drug include treatment for (1) cytomegalovirus retinitis in AIDS patients and (2) acyclovir-resistant mucocutaneous infections in immunocompromised patients [1] Group 2: Business Impact - The approval of this drug will further enrich the product portfolio of the company, enhancing its market position in the pharmaceutical industry [1]

Major Events - JD Industrial (07618) received a subscription rate of 60.52 times for its public offering in Hong Kong, with a share price set at HKD 14.10 [1] - Shanghai Pharmaceuticals (02607) obtained approval for the listing application of Succinic Acid Sultamicillin Tablets (SPH3127) [1] - Fosun Pharma (02196) received approval from the National Medical Products Administration for the drug registration application of Sodium Phosphonate Injection [1] - Lingbao Gold (03330) subsidiary plans to invest AUD 370 million to acquire a 50%+1 share stake in St Barbara Mining Pty Ltd [1] - Jiangsu Ninghu Expressway (00177) intends to increase capital by CNY 3.26964 billion to Longtan Bridge Company [1] - Yunfeng Financial (00376) had Fitch maintain the "A-" (Strong) financial strength rating for Wantong Insurance [1] Operating Performance - Sunny Optical Technology (02382) reported a shipment volume of 12.634 million vehicle-mounted lenses in November, a year-on-year increase of 69.4% [1] - Q Technology (01478) saw mobile camera module sales of 38.053 million units in November, a month-on-month decrease of 13.6% and a year-on-year decrease of 5.6% [1] - Yue Yuen Industrial (00551) reported a cumulative operating profit of approximately USD 7.382 billion for the first 11 months, a year-on-year decrease of 1.6% [1] - Baoshan International (03813) reported a cumulative operating profit of CNY 15.784 billion for the first 11 months, a year-on-year decline of 6.8% [1] - COFCO Joycome (01610) reported a pig slaughter volume of 559,000 heads in November, a month-on-month decrease of 4.44% [1]

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Sodium Foscarnet Injection, aimed at treating AIDS patients with cytomegalovirus retinitis and immunocompromised patients with acyclovir-resistant herpes simplex virus infections [1] Group 1 - The approved indication for Sodium Foscarnet Injection includes treatment for cytomegalovirus retinitis in AIDS patients [1] - The drug is also indicated for immunocompromised patients suffering from acyclovir-resistant herpes simplex virus infections [1]

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of Sodium Phosphonacetate Injection, which is indicated for the treatment of AIDS-related cytomegalovirus retinitis and herpes simplex virus skin and mucosal infections in immunocompromised patients [1]. Group 1: Product Details - Product Name: Sodium Phosphonacetate Injection [1] - Dosage Form: Injection [1] - Specification: 250ml:6g (calculated as CNa₃O₅P·6H₂O) [1] - Registration Classification: Class 3 Chemical Drug [1] - Marketing Authorization Holder: Guilin Pharmaceutical Co., Ltd. [1] - Drug Approval Number: National Drug Approval Code H20256094 [1] Group 2: Indications - Approved indications include treatment for (1) cytomegalovirus retinitis in AIDS patients and (2) herpes simplex virus skin and mucosal infections in patients with immune dysfunction [1].

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of Foscarnet Sodium Injection, expanding its product line and addressing specific medical needs [1] Group 1: Product Approval - The approved indications for Foscarnet Sodium Injection include treatment for (1) cytomegalovirus retinitis in AIDS patients and (2) acyclovir-resistant mucocutaneous infections in immunocompromised patients [1] Group 2: Financial Investment - As of November 2025, the total R&D investment for this drug by the group is approximately RMB 4.98 million (unaudited) [1] Group 3: Market Potential - According to IQVIA CHPA data, the sales revenue for Foscarnet Sodium Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 86.4 million in 2024 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of sodium phosphonate injection, which is indicated for the treatment of cytomegalovirus retinitis in AIDS patients and herpes simplex virus infections in immunocompromised patients [1] Group 1 - The approved drug is sodium phosphonate injection [1] - The indications for the drug include treatment for cytomegalovirus retinitis in AIDS patients [1] - The drug is also indicated for herpes simplex virus infections in patients with immune dysfunction [1]

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Guilin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Sodium Foscarnet Injection, which is indicated for the treatment of (1) cytomegalovirus retinitis in AIDS patients and (2) acyclovir-resistant mucocutaneous infections in immunocompromised patients [1] Group 1 - The drug approval expands the treatment options for AIDS patients suffering from cytomegalovirus retinitis [1] - The approval also addresses the needs of immunocompromised patients facing acyclovir-resistant infections [1]

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its sodium phosphonate injection, which is indicated for the treatment of cytomegalovirus retinitis in AIDS patients and acyclovir-resistant herpes simplex virus infections in immunocompromised patients [1] Group 1 - The approval of the sodium phosphonate injection will enhance Fosun Pharma's product line [1] - The sales performance of the newly approved drug is subject to various influencing factors, leading to uncertainty [1]